Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma: a retrospective cohort study based on SEER database
The mIDH had better 2-year relative survival compared to wIDH across all treatment modalities. Adjuvant chemotherapy had more than 20% survival benefit compared to radiotherapy in mIDH and wIDH. These results highlight adjuvant chemotherapy as the modality of choice for mIDH to improve the survival outcome and avoid radiotherapy's unfavorable side effects. The study was registered at Clinicaltrial.gov with identification number of NCT06620926.
Authors
- A. Ellaithy (ORCID: https://orcid.org/0000-0002-6997-9689)
- Nahla Ali (ORCID: https://orcid.org/0000-0002-4459-3464)
- Esraa Hamouda (ORCID: https://orcid.org/0000-0002-8766-797X)
- Mohamed Hassan (ORCID: https://orcid.org/0000-0001-8142-8073)
- Mohammad Hamad
- Bushra Al-Shaikh
- Heba Hamouda
Institutions
- Suez Canal University (EG)
- University of Jordan (JO)
- Sana'a University (YE)
- South Valley University (EG)
- Menoufia University (EG)
- Alexandria University (EG)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1097/ms9.0000000000003172
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00